January 27, 2023
Purpose-built economic zone enables life sciences companies to manage research, manufacturing, and distribution efforts from one strategic location
Abu Dhabi, UAE – 27 January 2023: As demand for domestic production of pharmaceuticals increases across the GCC region, Khalifa Economic Zones Abu Dhabi – KEZAD Group, the integrated trade, logistics, and industrial hub of Abu Dhabi, will showcase the competitive advantage Abu Dhabi offers to researchers, manufacturers and distributors looking at Arab Health 2023.
As the premier economic zone for life sciences in the Middle East and North Africa, KEZAD already hosts many pharmaceutical manufacturers, life science businesses, laboratories, packing businesses and supporting services, including several leading organisations such as Hope Consortium, ADCAN Pharma, Neopharma, Medisal, National Reference Laboratory, and Pharmatrade, including the G42, which announced the development of one of the largest vaccine production facilities in KEZAD last year.
During the event, KEZAD Group will demonstrate its capabilities for supporting industry growth and innovation through its Life Science ecosystem, located in the heart of Abu Dhabi, which is specifically designed for manufacturing, logistics, development and education activities in the field.
Currently spread across 1.6 square kilometres and supported by multi-modal transport links via land, sea, air, and upcoming rail, KEZAD’s healthcare and life science ecosystem offers fast set-up times for companies through a range of solutions including serviced land plots and diverse built-to-suit facilities, in addition to critical storage options with standard, cool and cold warehousing solutions available.
Strengthening government efforts to position the nation as a regional centre for pharmaceutical manufacturing, the ecosystem also benefits from strong institutional backing to facilitate rapid licensing, permitting, and product registration.
Mohamed Al Khadar Al Ahmad, CEO, Khalifa Economic Zones Abu Dhabi -KEZAD Group, said: “At Arab Health 2023, KEZAD Group will share its unique value proposition to accelerate growth and innovation within the region’s medical sector. As a leading facilitator of industry and manufacturing, KEZAD Group currently supports the operations of leading healthcare businesses via its Life Sciences Hub.
In addition to critical infrastructure, such as advanced cold-chain storage and blockchain management for safe and secure vaccine distribution, KEZAD Group offers unrivalled multimodal connectivity, linking healthcare businesses to global markets, with access to approximately 4.5 billion people worldwide.”
A leading showcase of the KEZAD’s capabilities in the sector lies in its critical role as part of the UAE-based HOPE Consortium, which facilitates the distribution of millions of COVID-19 vaccines across the world. AD Ports Group commissioned 19,000 m2 of cold storage warehouse space in the zone for the project, capable of storing more than 120 million COVID-19 vaccines, and continues to expand facilities for life-saving medication.
The annual Arab Health conference, which takes place from 30 January to 2 February at Dubai World Trade Centre, provides a vital arena for the region’s healthcare stakeholders to share insights on new developments within the industry, aiming to revolutionise healthcare for future generations